Moh’s Surgery More Effective than Excision for Recurrent Basal Cell Carcinoma

Cancer Connect

Mohs micrographic surgery (MMS) for the treatment of recurrent basal cell carcinoma (rBCC) of the face results in fewer recurrences than surgical excision, according to the results of a study published in the December 2008 issue of the Lancet Oncology.1

Skin cancer is often divided into two broad categories: melanoma and nonmelanoma. Nonmelanoma skin cancer refers to several different types of skin cancer, but the most common types are basal cell carcinoma and squamous cell carcinoma. Each year in the U.S., more than one million people are diagnosed with basal cell or squamous cell skin cancers. Unlike melanoma, these types of skin cancer are rarely deadly.

Basal cell carcinoma accounts for roughly 80% of all cases of nonmelanoma skin cancer. It most commonly develops on sun-exposed skin, with the head (particularly the nose) and neck being the most common sites. This type of skin cancer very rarely metastasizes (spreads beyond the skin), but it can cause extensive local damage to the skin and surrounding tissues.

Basal cell carcinoma is typically treated with either surgical excision or Mohs micrographic surgery (MMS). Surgical excision involves the use of a scalpel to remove the cancer and some surrounding normal tissue, which is then sent to the lab where the margins are checked for cancer. If the margins are clear, its likely that the cancer was completely removed. Mohs micrographic surgery is a more complicated procedure, during which a doctor removes thin layers of skin one at a time and evaluates them for cancer while the patient waits. The doctor keeps removing layers of skin until he or she reaches a layer that is cancer-free. This procedure removes the least amount of normal tissue, and also has the highest cure rates for both primary and recurrent cancers. The procedure generally requires less than four hours to complete but can take longer if the cancer is extensive.

In a study performed in the Netherlands, 408 primary BCCs (pBCC) and 204 recurrent BCCs (rBCC) were randomly assigned to surgical excision or MMS. After five years of follow-up, the researchers found that MMS produced significantly lower recurrence rates than surgical excision in the rBCC group. (Two patients in the rBCC group treated with MMS experienced a recurrence of cancer, versus ten patients treated with surgical excision.) However, in the group of patients with pBCC, there was not a significant difference between the two surgical modalities.

The researchers concluded that MMS is preferred over surgical excision for the treatment of facial rBCC because it produces significantly fewer recurrences.


[1] Mosterd K, Krekels GAM, Nieman FHM, et al. Surgical excision of Mohs micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years follow-up. LancetOncology. 2008; 9:1149-1156.

Copyright Skin Cancer Information Center on

Copyright © 2018 CancerConnect. All Rights Reserved.